[June 6, 2019] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, today announced that its Phase II clinical trial IND application of iVIEW-1201 for the Treatment of Adenoviral Conjunctivitis has been approved by Indian Regulatory Authority, CDSCO.[...]
[April 11, 2019] Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company focusing on topical drug and medical device development, today announced that it has received a Small Business Innovation Research (SBIR) Award from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH)[...]
[December 31, 2018] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that its Phase II clinical trial IND application of iVIEW-1201 was been accepted by US FDA. As Dr. Wendy Streight, FDA Regulatory Project Manager, said in her [...]
[June 27, 2018] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that it has closed its A round financing of close to $6 million dollars from both strategic and[...]
[April 26, 2018, Shanghai] Dr. Bo Liang, Chairman of iVIEW Therapeutics Inc., came to Zhongshan Eye Hospital, Shanghai to talk with Professor Fei Yuan, Chief Physician of Ophthalmology at Zhongshan Eye Hospital of Fudan University, about the collaboration for iVIEW-1201 project clinical trials in China for the treatment of viral conjunctivitis[...]
Website Language: 
Pennsylvania Biotechnology Center at Bucks County